Vaxxas

https://www.vaxxas.com/

Background

Vaxxas is commercializing innovative needle-free vaccine technology that boosts immune response and reduces reliance on refrigeration, easing distribution challenges. Validated in human trials, its proprietary dry-coating method enhances vaccine performance. Vaxxas is targeting initial applications in infectious disease and oncology, and collaborates with global leaders including Merck, BARDA, WHO, CEPI, and the Gates Foundation.